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ABSTRACT 
Abnormal coagulation parameters can be found in 25% of trauma patients with 
major injuries. Furthermore, trauma patients presenting with coagulopathy on 
admission have worse clinical outcome. Tissue trauma and systemic hypoperfusion 
appear to be the primary factors responsible for the development of acute traumatic 
coagulopathy immediately after injury. As a result of overt activation of the protein C 
pathway, the acute traumatic coagulopathy is characterized by coagulopathy in 
conjunction with hyperfibrinolysis. This coagulopathy can then be exacerbated by 
subsequent physiologic and physical derangements like consumption of coagulation 
factors, hemodilution, hypothermia, acidemia, and inflammation; all factors being 
associated with ongoing hemorrhage and inadequate resuscitation or transfusion 
therapies. Knowledge of the different mechanisms involved in the pathogenesis of 
acute traumatic coagulopathy is essential for successful management of bleeding 
trauma patients. Therefore, early evidence suggests that treatment directed at 
aggressive and targeted hemostatic resuscitation can lead to reductions in mortality 
of severely injured patients. 
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INTRODUCTION 
Trauma accounts for a significant proportion of death and disabilities worldwide 
and it is expected that trauma-related mortality will increase in the near future despite 
continuing advances in resuscitation, trauma surgery and critical care.1 
Uncontrollable hemorrhage and severe central nervous system injury are known to 
be the major causes of early death after injury,2 whereas hemorrhage has been 
shown to be responsible for a third of all trauma fatalities.3,4 
There are two basic mechanisms by which patients may bleed after trauma. First, 
hemorrhage may occur as a direct result of major injuries (i.e., anatomical bleeding). 
This bleeding is life-threatening and leads to hemorrhagic shock and exsanguination 
if not treated readily. Bleeding may be stopped temporarily by external compression 
and tourniquets, however, surgical or interventional (e.g., arterial embolization) repair 
is required for final hemorrhage control. Second, a disturbed coagulation system with 
diffuse microvascular bleeding may result in a hemorrhage that is no longer localized 
on the site of injury (i.e., coagulopathic bleeding). This uncontrolled non-surgical 
hemorrhage may complicate life-saving surgery and force the early termination of 
operations.5 
The adverse outcomes of perturbations in blood coagulation are not limited to 
death from acute blood loss.6 Organ dysfunction and multiple organ failure are 
potential consequences of severe injury with subsequent activation of the 
inflammatory cascade and prolonged shock states.3 Coagulation is an integral part of 
the inflammatory system and widespread activation of coagulation results in a 
systemic inflammatory response syndrome (SIRS) and increased susceptibility to 
infections and sepsis.7 This is exacerbated by the adverse immunologic effects of 
blood transfusions.8,9 Coagulopathy further worsens outcomes in patients having 
 4
 
sustained traumatic brain injury by an increased potential for progression of the 
intracranial hemorrhage and secondary neuronal loss.10,11 
Abnormal coagulation parameters can be found in 25% of patients with major 
trauma and is associated with worse clinical outcome in these patients.10,12-14 In the 
last years, there has been a renewed clinical interest to understand the role of the 
coagulation system in disease and to provide a global functional characterization of 
the causes and effects of traumatic coagulopathy. Early evidence suggests that 
treatment directed at aggressive and targeted hemostatic resuscitation can lead to 
dramatic reductions in mortality of severely injured patients.15-18 By specific and goal-
directed treatment guided by transfusion algorithms, the coagulopathic trauma patient 
may be optimized readily, thereby minimizing exposure to blood products, reducing 
costs and improving patient’s outcome.19-21 
ACUTE TRAUMATIC COAGULOPATHY – EARLY PHASE 
Traditionally, the acute traumatic coagulopathy has been thought to be due to lost 
or inhibited coagulation proteases. Loss may be absolute due to widespread 
activation and consumption of coagulation factors, or relative due to dilution from 
intravenous fluid therapy. Inhibition can occur due to physical factors such as 
hypothermia and acidosis.22 This coagulopathy has also been described previously 
as systemic acquired coagulopathy (SAC).23,24 
More recently, it has been recognized that some trauma patients present with an 
early coagulopathy that is physiologically and mechanistically distinct from the above 
mentioned coagulopathy, SAC. Two recent studies have identified an acute traumatic 
coagulopathy, present on arrival in the emergency department in 25% of patients with 
major trauma.10,12 This posttraumatic coagulopathy in the early phase, also called 
endogenous acute coagulopathy (EAC)23 or Acute Coagulopathy of Trauma-Shock 
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(ACoTS)25 is associated with higher transfusion requirements, a greater incidence of 
multiorgan dysfunction syndrome (MODS), longer ICU and hospital stays, and a 4-
fold increased risk of mortality compared to those with normal coagulation.10,12  
Tissue injury and systemic hypoperfusion 
In examining the mechanism for the coagulopathy in the early phase after trauma, 
our group recently reported that the combination of traumatic injury and tissue 
hypoperfusion resulted in a coagulopathy that was associated with a reduction in 
protein C levels.14 Protein C is a plasma serine protease and part of the natural 
anticoagulant pathways.26 The protein C anticoagulant pathway is initiated when 
thrombin binds to thrombomodulin (TM) on the surface of the endothelium. An 
endothelial cell protein C receptor (EPCR) further augments protein C activation by 
the thrombin–TM complex more than 10-fold in vivo. Once activated, activated 
protein C (aPC) exerts its anticoagulant effects by irreversibly inactivating factors Va 
and VIIIa.26 In addition, aPC has further anticoagulant activity through its de-
activation of plasminogen activator inhibitor 1 (PAI-1) resulting in enhanced 
fibrinolysis.27 
Injury severity is closely associated with the degree of coagulopathy.10,12 
However, severely injured patients with normal hemodynamics and no physiologic 
derangement (i.e. patients not being in shock) rarely present coagulopathic on 
admission and have a relatively low mortality rate.14,28 Systemic hypoperfusion (i.e., 
shock state) itself appears to play a central role in the pathogenesis of early traumatic 
coagulopathy. There is a dose-dependent association between the degree of tissue 
hypoperfusion and the level of admission coagulopathy as measured by prothrombin 
time (PT) and partial thromboplastin time (PTT).14,28 As the shock progresses there is 
an increase in plasma levels of soluble thrombomodulin and a decrease in protein C 
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levels.14 In the presence of tissue hypoperfusion, the endothelium seems to express 
thrombomodulin which complexes with thrombin to divert it to an anticoagulant 
function. Less thrombin is available to cleave fibrinogen and thrombin complexed to 
thrombomodulin activates protein C, which leads to coagulopathy (by inactivating 
factor Va and VIIIa) and hyperfibrinolysis (by inhibiting PAI-1). Corroborating this, we 
found that in the presence of tissue hypoperfusion and increased levels of 
thrombomodulin, platelet and fibrinogen levels remained normal, indicating that less 
thrombin was available to cleave fibrinogen (as it was complexed to thrombomodulin) 
and to consume platelets. 
While highly suggestive of an activated protein C mediated early traumatic 
coagulopathy, the above mentioned human data was observational and correlative, 
requiring mechanistic confirmation. Therefore, our group developed a translational 
mouse model of acute traumatic coagulopathy. Using this animal model, our research 
group demonstrated that the combination of tissue injury and tissue hypoperfusion is 
required to produce an early traumatic coagulopathy.23 Furthermore, the data 
demonstrates that the anticoagulant function of activated protein C is the primary 
mechanism responsible for the development of the acute traumatic coagulopathy in 
the early phase after injury. Selective inhibition of protein C’s anticoagulant function 
in this animal model effectively prevented the development of the acute traumatic 
coagulopathy in response to injury and hypoperfusion.23 This result is consistent with 
our published clinical observations that activation of the protein C pathway correlates 
with the development of the early, acute traumatic coagulopathy in injured and 
hypoperfused trauma patients. 
Hyperfibrinolysis is common after trauma and is a direct consequence of both 
tissue injury and shock. As mentioned above, it is mediated by de-inhibition of tissue 
plasminogen activator (tPA) through the consumption of PAI-1 by activated protein C. 
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Low levels of PAI-1, in combination with the increased release of tPA from the vessel 
wall will result in hyperfibrinolysis.29 Contrary to these findings, it has previously been 
suggested that the de-inhibition of fibrinolysis seen with protein C is not due to this 
mechanism (reduced PAI-1 activity) but due to a competitive reduction in TAFI 
(thrombin activatable fibrinolysis inhibitor) activation. TAFI is the main driver of 
fibrinolysis inhibition, and reduction in TAFI activation (by the competitive binding of 
protein C to thrombin-TM) has been described as the primary mechanism for de-
repression of fibrinolysis with activation of protein C.30-32 In our previous study 
however, we were able to demonstrate an increase in TAFI levels with 
thrombomodulin, and a competition between TAFI and protein C, but there was no 
observable correlation between TAFI and D-Dimer levels.29 Further confirmatory 
studies are required, but the consumption of PAI-1 by activated protein C appears to 
be the more clinically important cause of hyperfibrinolysis in trauma patients. Besides 
the mechanism of inhibiting PAI-1 through activated protein C, endothelial injury 
results in increased fibrinolysis because of the direct release of tPA.33 tPA expression 
by the endothelium is also increased in the presence of thrombin.34 Fibrinolysis is 
exacerbated because of the combined effects of endothelial tPA release due to 
ischemia35,36 and inhibition of plasminogen activator inhibitor-1 (PAI-1) in shock.14 
Additionally, in the presence of reduced thrombin concentrations, fibrin monomers 
polymerize abnormally and are more susceptible to cleavage by plasmin.37 The 
purpose of this hyperfibrinolysis is presumably to limit clot propagation to the site of 
vascular injury. With widespread trauma, however, such localization may be lost.25 
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Inflammation 
The complement system occupies a central role in innate immunity and becomes 
activated early after trauma in humans.38,39 Our group has recently reported that 
there is an amplified activation of complement via the alternative pathway that occurs 
nearly immediately after injury.40 Complement activation correlated with injury 
severity and tissue hypoperfusion and was associated with increased mortality and 
with the development of organ failure, such as acute lung injury and acute renal 
failure.40 Furthermore, complement has been well studied in ischemia and 
reperfusion. Stahl and colleagues have identified the lectin pathway as being the 
dominant mechanism of complement activation during ischemia/reperfusion, and 
have shown that mannose binding lectin (MBL) binds to a complex of IgM and self-
antigens exposed at the surface of endothelial cells during ischemia.41 This complex 
then activates the MBL dependent portion of the lectin complement pathway. While 
complement is independently an important mediator of cell injury following tissue 
hypoperfusion and shock, the link between complement and coagulation is also 
strong and well described.42 
Is there an association between activation of complement and the protein C 
pathway? Previous studies have reported a direct link between the protein C pathway 
and complement through thrombin activatable fibrinolysis inhibitor (TAFI). TAFI is a 
carboxypeptidase which, like protein C, is activated by the thrombin-TM complex and 
which inhibits fibrinolysis by prevention of plasminogen binding as mentioned 
above.31 TAFIa acts directly on complement, cleaving and inactivating C3a and C5a 
providing a link between thrombin, TM, aPC, and the anaphylatoxins of 
complement.43 Furthermore, our group has reported evidence of an MBL initiated 
activation of the alternative pathway of complement after trauma.40 In addition, some 
preliminary unpublished data from our group showed a significant correlation 
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between complement activation, protein C activation, and traumatic coagulopathy in 
humans. Furthermore, TM expression and protein C activation after ischemia-
reperfusion seems to be complement-dependent, indicating a link between 
complement activation and the early phase of acute traumatic coagulopathy caused 
by hemorrhage and severe trauma (Figure 1).  
TRAUMATIC COAGULOPATHY – LATER PHASE 
In the later phase after trauma, acute traumatic coagulopathy mediated through 
tissue injury and shock may be worsened by the classically known causes of 
traumatic coagulopathy, i.e., consumption, dilution, acidosis and hypothermia. The 
inflammatory cascade thereby plays a further role, central but complex, as there is a 
significant cross-talk between the coagulation and inflammatory system.44 
Activation and Consumption 
Tissue injury leads to vascular damage with expression of subendothelial 
structures into the circulatory system thereby expressing tissue factor and initiating 
the clotting cascade. The severity of injury has been shown to directly correlate with 
the amount of thrombin generated and activation of the coagulation cascade results 
in consumption of coagulation factors.14 However, there is little evidence to support 
consumption of clotting factors as a relevant mechanism for the early phase of the 
acute traumatic coagulopathy: in patients without systemic hypoperfusion, 
coagulation parameters like PT and PTT were typically not prolonged regardless of 
the amount of thrombin formed.14 Furthermore, platelets and fibrinogen levels were 
within normal ranges in patients with acute traumatic coagulopathy.14,29  
Specific injury patterns like severe traumatic brain injury or long bone fractures 
are frequently associated with the development of a coagulopathy.45-47 In patients 
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with traumatic brain injury, it has been postulated that brain-specific thromboplastins 
are released into the circulation, with subsequent inappropriate consumption of 
coagulation factors causing a disseminated intravascular coagulation (DIC) like 
coagulopathy.48 There is, however, no evidence to support this DIC hypothesis in the 
early phase after trauma. More recent data suggest that hyperfibrinolysis due to 
tissue damage and hypoperfusion with consecutive activation of the protein C 
pathway may be the predominant mechanism of coagulopathy in these patients.49-51 
The same holds true for multiple long-bone fractures with marrow fat embolization. 
Here, it appears that the resulting coagulopathy is also caused by tissue injury, shock 
and inflammation, rather than through a bone marrow-specific pathogenesis.52 The 
use of DIC to describe traumatic coagulopathy is therefore misleading and should be 
avoided. 
Dilution 
Dilutional coagulopathy is one of the most common causes of bleeding after 
massive transfusion in the later phase after trauma.15,53 Hemorrhagic shock leads to 
a net flux of extracellular water into the vascular space because of a lowered 
intravascular hydrostatic pressure due to bleeding. This dilution of coagulation 
proteins is further enhanced by external fluid resuscitation. In addition to the dilutional 
effect, which may be calculated mathematically, side effects on coagulation from 
different fluids (e.g., crystalloids, colloids) with different compositions (e.g., 
unbalanced vs. balanced solutions; normotonic vs. hypertonic solutions) have to be 
considered.54-56 
It is still unclear which type of fluid should be employed in the initial treatment of 
the bleeding trauma patient.19 Although several meta-analyses have shown an 
increased risk of death in patients treated with colloids compared with patients 
 11
 
treated with crystalloids57-61 and three of these studies showed that the effect was 
particularly significant in a trauma subgroup,57,59,60 a more recent meta-analysis 
showed no difference in mortality between colloids and crystalloids.62 The SAFE 
(Saline vs. Albumin Fluid Evaluation) study compared 4% albumin with 0.9% sodium 
chloride in a large number of ICU patients and showed that albumin administration 
was not associated with worse outcomes; however, there was a trend toward higher 
mortality in the trauma subgroup that received albumin.63 
Several studies have shown that infusion of colloid plasma expanders induces 
coagulopathy to a greater extent than simple dilution, thereby increasing the risk of 
bleeding.53,54,64 Several mechanisms have been proposed: some studies have shown 
that colloids may reduce levels of von Willebrand factor (vWF) and factor VIII,65,66 
whereas other studies have reported on masked expression of glycoprotein IIb/IIIa on 
activated platelets.67,68 More recently, an acquired deficiency of fibrinogen with 
abnormal fibrin polymerization have been proposed as the main determinant of 
dilutional coagulopathy.69,70 The dilutional coagulopathy observed after administration 
of moderate amounts of hydroxyethyl starch solutions could be completely corrected 
by administration of fibrinogen concentrate. Additionally, bleeding and postoperative 
transfusion requirements were significantly reduced after reversing this dilutional 
coagulopathy by fibrinogen concentrate.69,70 Fibrinogen is the final substrate in the 
clotting cascade and has been described as the earliest coagulation factor to reach a 
critically low threshold level in bleeding patients.71 Furthermore, fibrinogen has been 
suggested as a key coagulation factor needed to ensure sufficient and stable 
hemostasis during severe hemorrhage.72-74 
Transfusion of packed red blood cells (pRBCs) also result in dilution of clotting 
factors and reduction in clotting ability.15,22,75 PRBCs contain no functional platelets 
and only little plasma. By the time 10-12 units of pRBCs have been administered, at 
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least two third of the patient’s original plasma has been lost. At that time, a 
prolongation of PT and PTT will be measurable by more than 1.5 times mid-range of 
normal.76,77 Platelets are lost more slowly than plasma proteins because a third of 
platelets are sequestered in the spleen and an additional fraction are adherent to the 
endothelium. As a result, platelet counts rarely fall below 100,000/mm3 before 10-20 
units of pRBCs have been administered in situations of otherwise uncomplicated 
hemorrhage. In a study of 39 massively transfused patients, platelet counts below 
50,000/mm3 were found in three of four patients who received 20 or more units of red 
blood cell products and in no patients who received less than 20 units.77 As a rule of 
thumb recognized for a long time, these data suggest that coagulation factor 
replacement is mandatory at the latest in patients who receive 12 or more units of 
pRBCs, and platelet replacement is necessary in patients who receive 20 or more 
units of pRBCs.77,78 
Acidosis 
The association between high lactate levels and increasing risk of death was first 
described over 40 years ago.79 Since then, several investigators have demonstrated 
increasing risk of death with metabolic acidosis as demonstrated by arterial pH, 
lactate, and base deficit clearance.80 The deleterious effects of acidosis on the 
cardiovascular system include decreased cardiac contractility and cardiac output, 
vasodilation and hypotension, decreased hepatic and renal blood flow, bradycardia, 
and increased susceptibility to ventricular dysrhythmias.81 Acidosis directly reduces 
the activity of the extrinsic and intrinsic coagulation pathways as measured by PT 
and PTT and also diminishes platelet function as measured by platelet aggregation. 
These adverse effects are generally not seen until pH decreases below 7.2.82 
Therapy for metabolic acidosis remains directed toward correcting the underlying 
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tissue hypoperfusion. Resuscitation endpoints include normalization of arterial pH, 
base deficit, and lactate. Interestingly, simple correction of the acidosis by buffer 
therapy does not seem to correct the negative effects of acidemia on coagulation.83,84 
Clinical trials have failed to demonstrate any clear advantage of bicarbonate 
administration, whereas the potential adverse effects are well documented.85  
If transfusions with pRBCs are required, the following storage effects on acid-
base homeostasis have to be considered: after 2 weeks of storage, pRBCs have a 
pH below 7.0, and each unit has an acid load of approximately 6 mEq.86 One of these 
mEq of acid comes from the fact that pRBCs are made from venous blood with a 
starting pH of 7.35, a second mEq is acquired in buffering the citric acid in the 
anticoagulant, and 4 mEqs are generated by glycolysis during pRBC storage. Seven 
units of pRBCs are expected to increase the whole body base deficit of a 70 kg man 
by 1 mEq/L. 
Hypothermia 
Hypothermia is a frequent consequence of severe injury and subsequent 
resuscitation. It is estimated that as many as 66% of trauma patients arrive in the 
emergency department with hypothermia.87 Gregory and colleagues found that 
hypothermia developed at some point in 57% of the trauma patients studied, and that 
temperature loss was most severe in the emergency department setting.88 There is, 
however, very little effect of hypothermia on coagulation protease function and 
clinical bleeding at temperatures above 33°C.82,89,90 On the other side, body 
temperatures less than 33°C produce a clinically significant coagulopathy that is 
functionally equivalent to factor deficiency states seen when coagulation factor 
concentrations are less than 50%.91 Thrombin generation on platelets is reduced by 
25% at 33°C. The average size of aggregates formed by thrombin activated platelets 
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was decreased by 40% at 33°C and platelet adhesion was reduced by 33%.92 
Adverse clinical effects such as cardiac dysrhythmias, reduction in cardiac output, 
increase in systemic vascular resistance, and a left shift in the oxygenhemoglobin 
saturation curve have been described. Mortality rates as high as 100% are seen in 
patients with severe hypothermia and severe injury. The most significant effect of 
hypothermia in trauma is coagulopathic bleeding due to prolonged clotting cascade 
enzyme reactions, dysfunctional platelets, and fibrinolysis.91,92 
Resuscitation with cold blood and fluids creates a vicious cycle of worsening 
hemodilution, acidosis, hypothermia, and coagulopathy. Interestingly, five units of 
cold pRBCs would be expected to reduce the body temperature of a 70 kg man by 
about 1°C.86 
Inflammatory response to injury 
In the later course after injury, the inflammatory response shifts the hemostatic 
mechanisms in favor of thrombosis (Figure 2). Multiple mechanisms are at play 
including up regulation of tissue factor leading to the initiation of clotting, amplification 
of the clotting process by augmenting exposure of cellular coagulant phospholipids, 
inhibition of fibrinolysis by elevating plasminogen activator inhibitor 1 (PAI-1) and 
decreases in natural anticoagulant pathways, particularly targeted toward down 
regulation of the protein C anticoagulant pathway through multiple mechanisms.7,44 
Part of the explanation for this may lie in the early activation of protein C resulting in 
protein C depletion. As protein C is synthesized in the liver, it will take several days 
for protein C levels to return to normal, during which time a hypercoagulable state will 
exist that is known to predispose to venous thrombosis.93 Patients who present with 
coagulopathy on admission should therefore be considered at increased risk of deep 
venous thrombosis and pulmonary embolism and receive prophylaxis accordingly. 
 15
 
Activated protein C also acts via the cell surface receptor, protease-activated 
receptor-1 (PAR-1) to produce several cytoprotective effects.94 These effects include 
anti-inflammatory properties, anti-apoptotic activity and protection of endothelial 
barrier function.95-97 TNF α and other inflammatory mediators can down-regulate 
EPCR and TM and IL-6 can depress levels of protein S in experimental animals. A 
depleted or inhibited protein C pathway function increases cytokine elaboration, 
endothelial cell injury and leukocyte extravasation in response to endotoxin, 
processes that are decreased by infusion of aPC.7,44 Since thrombin can elicit many 
inflammatory responses in microvascular endothelium, loss of control of 
microvascular thrombin generation due to impaired protein C pathway function 
probably contributes to microvascular dysfunction, infections and end-organ injury in 
the later phase after trauma (Figure 2). 
CONCLUSIONS AND SUMMARY 
Tissue trauma and shock with systemic hypoperfusion appear to be the primary 
factors responsible for the development of acute traumatic coagulopathy in the 
immediate post-injury phase. As a result of overt activation of protein C pathway, the 
acute traumatic coagulopathy is characterized by coagulopathy in conjunction with 
hyperfibrinolysis.21 This coagulopathy can then be exacerbated by subsequent 
physical and physiologic derangements associated with ongoing hemorrhage and 
inadequate resuscitation or transfusion therapies. 
Knowledge of the different mechanisms involved in the pathogenesis of acute 
traumatic coagulopathy has clear significance for the successful management of 
bleeding trauma patients. In the early phase after trauma, efforts at augmenting the 
clotting factor pathway through pre-emptive blood transfusions and factor 
concentrates may prove ineffective until shock and associated hypoperfusion are 
 16
 
corrected. Underlining our hypothesis, other research groups recently suggested a 
revised bloody vicious cycle (hypothermia, acidosis, coagulopathy)98 with an “FFP 
resistant” pathway (endogenous acute coagulopathy, EAC) as opposed to a later 
“FFP sensitive” route leading to progressive systemic acquired coagulopathy (SAC) 
with associated clotting factor deficiency.99,100 To provide optimal care to 
hemorrhaging trauma patients and to prevent further bleeding, the leading 
pathomechanism of coagulopathy needs to be diagnosed and treated readily. 
Aggressive and goal-directed hemostatic resuscitation can thereby minimize 
exposure to blood products, reduce costs and improving patient’s outcome.15-17,19-21 
 
 
 17
 
PRACTICE POINTS 
 25% of trauma patients present with a clinically significant coagulopathy in the 
emergency department on arrival. 
 Trauma patients with coagulopathy on admission to the emergency department 
are four times more likely to die. 
 The acute coagulopathy of trauma in the early phase is due to shock with 
systemic hypoperfusion and consecutive activation of the thrombomodulin-protein 
C pathway (endogenous acute coagulopathy, EAC). 
 Knowledge of the different mechanisms involved in the pathogenesis of acute 
traumatic coagulopathy has clear significance for the successful management of 
bleeding trauma patients. 
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RESEARCH AGENDA 
 The exact molecular mechanisms by which the thrombomodulin-protein C 
pathway is getting activated needs to be further elaborated in trauma patients. 
 What happens to the other natural anticoagulant pathways after trauma ? 
 The complex interaction between inflammation and coagulation in trauma patients 
needs further in depths studies. 
 What are the mechanisms of an exhausted thrombomodulin-protein C pathway 
after trauma on patient outcome ? 
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FIGURE LEGENDS 
Figure 1: Early post-traumatic phase. Tissue trauma and shock with systemic 
hypoperfusion appear to be the primary factors responsible for the development of 
acute traumatic coagulopathy in the immediate post-injury phase. As a result of overt 
activation of protein C pathway, the acute traumatic coagulopathy is characterized by 
coagulopathy (de-activation of the coagulation factors Va and VIIIa) in conjunction 
with hyperfibrinolysis (de-repression of fibrinolysis). In addition to its anticoagulant 
effects, activated protein C proteolytically activates the cell surface receptor, 
protease-activated receptor-1 (PAR-1), to produce several cytoprotective effects 
including anti-inflammatory properties, anti-apoptotic activity and protection of 
endothelial barrier function, all being required for acute survival during shock. The 
complement cascade is being activated immediately after trauma via the lectin 
pathway (mannose binding lectin, MBL), amplified via the alternative pathway and 
seems to be implicated in the activation of the protein C pathway early after severe 
trauma.  
  
Figure 2: Late post-traumatic phase. In the later phase after trauma, there is the 
development of a pro-coagulant activity associated with low plasma levels of 
activated protein C (aPC), an inhibition of the fibrinolysis caused by elevated plasma 
levels of plasminogen activator inhibitor 1 (PAI-1) and a downregulation of 
complement activation due to low plasma levels of mannose-binding lectins (MBL) 
and significant impairment of C3b deposition via the lectin and alternative pathways. 
These coagulation and complement abnormalities increase the susceptibility to 
hypercoagulability with late thrombosis, infection and end-organ injury. At the later 
time points the dashed lines represent inhibited or depleted pathways 
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